TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Proteon Therapeutics Inc (NASDAQ:PRTO) Investor Investigation Concerning Possible Securities Laws Violations Announced

  • If you purchased shares of Proteon Therapeutics Inc (NASDAQ:PRTO), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
Proteon Therapeutics Inc
Security
NASDAQ: PRTO

Summary

April 3, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Proteon Therapeutics Inc (NASDAQ:PRTO) shares over potential securities laws violations by Proteon Therapeutics Inc and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Proteon Therapeutics Inc (NASDAQ:PRTO) concerning whether a series of statements by Proteon Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Waltham, MA based Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease.

On December 13, 2016, Proteon Therapeutics Inc announced that vonapanitase did not meet its primary endpoint in its first Phase 3 PATENCY-1 clinical trial.

Start Monitoring Your Investments